World Cancer Day is a day to raise awareness of cancer and to encourage its prevention, detection, and treatment. Led by the Union for International Cancer Control (UICC), its primary goal is to support collaborative efforts to significantly reduce the illness and death caused by cancer. The UICC’s theme for World Cancer Day 2024 is …
Over the last few years, a team of investigators at Johns Hopkins University conducted an innovative clinical trial designed to test the potential to induce an immune response against fibrolamellar carcinoma with a FLC-specific therapeutic vaccine. Participants in the clinical trial were given an experimental vaccine containing a peptide (a small segment of a protein) …
FCF is pleased to announce the establishment of a research collaboration with X-Chem, a global leader in DNA-encoded library (DEL) technology. Through the effort, X-Chem will leverage its powerful DEL platform to support drug discovery efforts against fibrolamellar’s difficult-to-drug fusion protein. The hope is that this powerful screening technology can be used to identify potential …
As we stand on the cusp of a brand new year, the Fibrolamellar Cancer Foundation extends warm wishes to the entire fibrolamellar community. May the coming year bring: FCF is committed to work collaboratively to build a brighter future for those touched by this disease. Please join us in the effort to reduce the fear …
Each year, the Tuesday after Thanksgiving celebrates giving as a way to transform the world. Giving Tuesday was created in 2012 as a day that encourages people to “do good”. Over the past 11 years, this idea has grown into a global movement that inspires hundreds of millions of people to give, collaborate, and celebrate generosity …
FCF is please to announce that it has funded a new study directed by Roshni Dasgupta, MD of the Cincinnati Children’s Hospital Medical Center (CCHMC). Dr. Dasgupta is a leader in surgical oncology and the chair of the Pediatric Surgical Oncology Research Collaborative (PSORC). PSORC includes 41 member institutions and has a mission “to improve …
This week, a new clinical trial of a peptide vaccine treated its first patient in Tübingen, Germany. The trial, named FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition is expected to enroll 20 patients with fibrolamellar carcinoma or other cancers carrying the DNAJB1-PRKACA fusion transcript. Study goals This phase I study will examine …
Thanks to the efforts of FCF’s Patient & Caregiver Advisory Board, we will be producing fibrolamellar calendars in 2024!
FCF has awarded a grant for additional studies to be conducted by John Scott, PhD of the University of Washington in Seattle. As the Chair of the Department of Pharmacology, Dr. Scott has been a key leader of a multi-disciplinary team working on FLC at the University of Washington and the Fred Hutchinson Cancer Center …